KOL Insight - Hepatocellular Carcinoma

This report provides a detailed analysis of current and emerging biologic and pipeline therapies in the hepatocellular carcinoma (HCC) market. Based on insights from 12 key opinion leaders, it examines the declining use of Cabometyx and Stivarga, the minimal impact of Cyramza, and the limited disruption expected from Tevimbra/Tizveni. The report also explores the use of Tecentriq plus Avastin, the uptake of Imfinzi and Imjudo, and the implications of recent clinical trials on the HCC treatment paradigm. Gain a comprehensive understanding of the factors influencing treatment preferences, the challenges new therapies face, and the evolving treatment algorithms.

Key Questions Answered:

• How do KOLs use Tecentriq plus Avastin in HCC treatment?
• Has the IMbrave050 data changed Tecentriq's adjuvant use?
• Where does Imfinzi plus Imjudo fit in the current treatment algorithm?
• How do KOLs view Opdivo plus Yervoy for first-line HCC?
• What is the expert take on LEAP-012 and CheckMate -9DW trial results?
• How are trials like IMbrave251 and EMERALD-2 shaping the landscape?
• How do KOLs use Lenvima, Stivarga, Cabometyx and Cyramza today?
• Which pipeline therapies excite experts the most for HCC?

Key Brands:

Partial List of Participating Experts:

• Professor, Medical Director of the Liver Tumor Program and Chief of Hepatology, University of Texas Southwestern Medical Center, TX
• Assistant Professor, Medical Director of the Multidisciplinary Liver Tumor Clinic and Medical Director of the Living Donor Liver Transplantation Program, Michigan, US
• Assistant Professor in the Division of Gastroenterology and Hepatology at the School of Medicine, Stanford University, CA
• Hepatologist at the Liver Unit, Barcelona Clinic Liver Cancer (BCLC) group, ICMDM, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
• Clinician Scientist and Consultant Medical Oncologist, Department of Surgery and Cancer, Imperial College London, London, UK
• Full Professor, Department of Medical and Surgical Sciences, University of Bologna, Italy

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.